Patient Alert: Our scheduling system is back online. The appointment reminder system is still down, appointment reminders are not currently being sent.

Trial Protocol ID
USOR 21498_VS-6766-203_RAMP203

Investigator
Nicholas J. Farrell, M.D.

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Trial Protocol ID
1479-0001 *RIT*

An open label, Phase I dose escalation trial, with dose confirmation and expansion, of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations

Trial Protocol ID
USOR 19151_849-001 *STAR*

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Trial Protocol ID
USOR 22198_FURMO-004 *STAR* & *RIT*

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Trial Protocol ID
USOR 21318_BO42777 *STAR*

A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCER

Trial Protocol ID
USOR 20412_J2G-MC-JZJX_LIBRETTO-432 *STAR*

A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432)

Trial Protocol ID
USOR 20139_D516AC00001 *STAR*

A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)

Trial Protocol ID
USOR 22123_1403-0011_Brightline-2 *STAR*

A Phase IIa/IIb, open-label, single-arm, multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours

Trial Protocol ID
USOR 22229_DS1062-A-U303_TROPION-Lung07

Investigator
Andrew Mener, M.D.

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)

Trial Protocol ID
USOR 22093_XB002-101_Jewel-101

Investigator
Yousuf A. Gaffar, M.D.

A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 AS SINGLE-AGENT AND COMBINATION THERAPY IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (XB002-101)

Trial Protocol ID
USOR 21541_DS1062-A-U304_TROPION-Lung08

Investigator
Vinni Juneja, M.D.

A Randomized, Open-Label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs. Pembrolizumab
Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-Small Cell Lung Cancer without Actionable Genomic Alterations (Tropion-Lung08)

Trial Protocol ID
USOR 22285_22285

Investigator
Kashif Ali, M.D.

MYLUNG Consortium Part 3: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study

Trial Protocol ID
USOR 21320_ONC-003

Investigator
John Wallmark, M.D.

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Patients with Advanced, EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer who have Progressed after Treatment with Osimertinib (Acclaim-1 Trial)

Trial Protocol ID
APL-101-01_SPARTA

Investigator
Kashif Ali, M.D.

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met Exon 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors